Literature DB >> 19922748

Transcutaneous electroporation mediated delivery of doxepin-HPCD complex: a sustained release approach for treatment of postherpetic neuralgia.

Srinivasa M Sammeta1, Siva Ram K Vaka, S Narasimha Murthy.   

Abstract

The electroporation mediated transdermal delivery (Protocol - 120 V, 10 ms, 30 pulses at 1 Hz with post pulse waiting period of 20 min) of doxepin using pure drug solution (PDS) and doxepin-hydroxypropyl-beta-cyclodextrin (HPCD) complex solution (CDS) was studied using porcine epidermis model. The stoichiometry of drug-HPCD inclusion complex was determined by differential scanning calorimetry (DSC). The amount of doxepin retained in the epidermis following electroporation did not differ significantly between PDS and CDS. When the drug loaded epidermis was subjected to "Release studies", doxepin release attained a plateau within approximately 2.5 days in case of PDS, whereas in case of CDS, doxepin release was prolonged up to 5 days. Mechanistic studies across the nonbiological barriers demonstrated that the slow dissociation of complex was responsible for sustained release of drug from the epidermis. Pharmacodynamic studies were carried out by electroporation mediated delivery of CDS and PDS in hairless rats. The analgesic effect of doxepin was prolonged in case of CDS as compared to PDS. (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922748      PMCID: PMC2833225          DOI: 10.1016/j.jconrel.2009.10.036

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  33 in total

Review 1.  Iontophoretic drug delivery.

Authors:  Yogeshvar N Kalia; Aarti Naik; James Garrison; Richard H Guy
Journal:  Adv Drug Deliv Rev       Date:  2004-03-27       Impact factor: 15.470

Review 2.  Skin electroporation for transdermal and topical delivery.

Authors:  Anne-Rose Denet; Rita Vanbever; Véronique Préat
Journal:  Adv Drug Deliv Rev       Date:  2004-03-27       Impact factor: 15.470

3.  Local and transient structural changes in stratum corneum at high electric fields: contribution of Joule heating.

Authors:  U Pliquett; S Gallo; S W Hui; Ch Gusbeth; E Neumann
Journal:  Bioelectrochemistry       Date:  2005-09       Impact factor: 5.373

Review 4.  The biochemistry and function of stratum corneum lipids.

Authors:  N Y Schurer; P M Elias
Journal:  Adv Lipid Res       Date:  1991

5.  Postherpetic neuralgia: the never-ending challenge.

Authors:  David Niv; Alexander Maltsman-Tseikhin
Journal:  Pain Pract       Date:  2005-12       Impact factor: 3.183

6.  In vivo noninvasive evaluation of hairless rat skin after high-voltage pulse exposure.

Authors:  R Vanbever; D Fouchard; A Jadoul; N De Morre; V Préat; J P Marty
Journal:  Skin Pharmacol Appl Skin Physiol       Date:  1998 Jan-Feb

7.  Lipid and electroosmosis enhanced transdermal delivery of insulin by electroporation.

Authors:  S Narasimha Murthy; Ya-Li Zhao; Khin Marlan; Sek Wen Hui; A Latif Kazim; Arindam Sen
Journal:  J Pharm Sci       Date:  2006-09       Impact factor: 3.534

8.  Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery.

Authors:  Tak-Wah Wong; Ching-Hung Chen; Chien-Chun Huang; Cheng-De Lin; Sek-Wen Hui
Journal:  J Control Release       Date:  2005-12-13       Impact factor: 9.776

9.  Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation.

Authors:  R Vanbever; G Langers; S Montmayeur; V Préat
Journal:  J Control Release       Date:  1998-01-02       Impact factor: 9.776

10.  Cutaneous analgesia after transdermal application of amitriptyline versus lidocaine in rats.

Authors:  Anna Haderer; Peter Gerner; Grace Kao; Venkatesh Srinivasa; Ging Kuo Wang
Journal:  Anesth Analg       Date:  2003-06       Impact factor: 5.108

View more
  9 in total

Review 1.  Skin permeabilization for transdermal drug delivery: recent advances and future prospects.

Authors:  Carl M Schoellhammer; Daniel Blankschtein; Robert Langer
Journal:  Expert Opin Drug Deliv       Date:  2014-01-07       Impact factor: 6.648

2.  The experimental evaluation and molecular dynamics simulation of a heat-enhanced transdermal delivery system.

Authors:  Daniel P Otto; Melgardt M de Villiers
Journal:  AAPS PharmSciTech       Date:  2012-12-11       Impact factor: 3.246

Review 3.  Getting Drugs Across Biological Barriers.

Authors:  Rong Yang; Tuo Wei; Hannah Goldberg; Weiping Wang; Kathleen Cullion; Daniel S Kohane
Journal:  Adv Mater       Date:  2017-07-28       Impact factor: 30.849

4.  Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen.

Authors:  Punit P Shah; Pinaki R Desai; Mandip Singh
Journal:  J Control Release       Date:  2011-11-21       Impact factor: 9.776

Review 5.  Transdermal drug delivery: feasibility for treatment of superficial bone stress fractures.

Authors:  Ali Aghazadeh-Habashi; Yang Yang; Kathy Tang; Raimar Lőbenberg; Michael R Doschak
Journal:  Drug Deliv Transl Res       Date:  2015-12       Impact factor: 4.617

6.  Downregulation of immunological mediators in 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions by hydrocortisone-loaded chitosan nanoparticles.

Authors:  Zahid Hussain; Haliza Katas; Mohd Cairul Iqbal Mohd Amin; Endang Kumolosasi; Shariza Sahudin
Journal:  Int J Nanomedicine       Date:  2014-11-05

7.  Efficient immuno-modulation of TH1/TH2 biomarkers in 2,4-dinitrofluorobenzene-induced atopic dermatitis: nanocarrier-mediated transcutaneous co-delivery of anti-inflammatory and antioxidant drugs.

Authors:  Zahid Hussain; Haliza Katas; Mohd Cairul Iqbal Mohd Amin; Endang Kumolosasi
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 8.  Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.

Authors:  Zhiguo Li; Xuexun Fang; Dahai Yu
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

Review 9.  Perspectives on Transdermal Electroporation.

Authors:  Kevin Ita
Journal:  Pharmaceutics       Date:  2016-03-17       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.